Resminostat tolerability, pharmacokinetics and pharmacodynamics in cancer patients (phase I trial)
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2013
At a glance
- Drugs Resminostat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- 18 Sep 2009 Results will be presented at the ECCO - ESMO Cancer Conference on 21 September 2009, according to a 4SC media release.
- 02 Jun 2009 Results presented at ASCO 2009.
- 09 Dec 2008 Final evaluation of all data is planned for the first quarter of 2009.